A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
← catalyst calendarNCT07446101 · readout ≤ 193 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
450estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-24 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Intervention
- Drug: Mirikizumab — also filed as LY3074828
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Maximum Concentration (Cmax) of LY3074828
measured Day 1 through Day 71
PK: Area Under the Concentration Versus Time Curve (AUC)(0-∞) of LY3074828
measured Day 1 through Day 71
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed